5 assets in Familial Alzheimer Disease

Therapeutic assets addressing Familial Alzheimer Disease, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Lecanemab Familial Alzheimer Disease	Washington University School of Medicine	P3	BB (66)
Immunoglobulin G1 [De-449-Lysine], Anti-(Human Tau Protein) (Human-Mus Musculus Monoclonal E2814 ?1-Chain), Disulfide With Human-Mus Musculus Monoclonal E2814 .Kappa.-Chain, Dimer Familial Alzheimer Disease	Washington University School of Medicine	P2/3	B (57)
Remternetug Familial Alzheimer Disease	Washington University School of Medicine	P2/3	B (57)
Solanezumab Familial Alzheimer Disease	Washington University School of Medicine	P2/3	CCC (54)
Immunoglobulin G1, Anti-(Human 1-40-.Beta.-Amyloid/Human 1-42-.Beta.-Amyloid) (Human Monoclonal .Gamma.1-Chain), Disulfide With Human Monoclonal .Kappa.-Chain, Dimer Familial Alzheimer Disease	Washington University School of Medicine	P2/3	CC (46)